Abstract
Radiochemotherapy represents the cornerstone of the treatment for patients affected by locally advanced non small cell lung cancer. Nevertheless, to date there is no agreement concerning how the standard therapy is and many questions are still open. Two timing modalities have been proposed to combine chemotherapy and radiotherapy: after many phase II/III have tested concurrent or sequential approach, concurrent radiochemotherapy is today considered as the treatment of choice, despite the role of induction or consolidation chemotherapy is still unclear. Cisplatin alone or in combination is considered as the reference drug in combination with chemotherapy, but in the last decades, many trials have demonstrated that new-generation drugs, which are routinely used in metastatic disease, may be used during radiotherapy and may enhance its tumor control rate, frequently having a radiosentizing power. Finally, in the era of molecular biomarkers and target therapies, new approaches could dramatically change the physicians view about the drug choice giving the opportunity of a tailored therapy customized on the single patient also in the treatment of locally advanced non-small cell lung cancer.
Keywords: Non-small cell lung cancer, chemotherapy, radiotherapy, target therapy, radiosensitizing agents
Current Drug Therapy
Title: Radiochemotherapy for Non Small Cell Lung Cancer
Volume: 5 Issue: 3
Author(s): Orazio Caffo and Viviana Murgia
Affiliation:
Keywords: Non-small cell lung cancer, chemotherapy, radiotherapy, target therapy, radiosensitizing agents
Abstract: Radiochemotherapy represents the cornerstone of the treatment for patients affected by locally advanced non small cell lung cancer. Nevertheless, to date there is no agreement concerning how the standard therapy is and many questions are still open. Two timing modalities have been proposed to combine chemotherapy and radiotherapy: after many phase II/III have tested concurrent or sequential approach, concurrent radiochemotherapy is today considered as the treatment of choice, despite the role of induction or consolidation chemotherapy is still unclear. Cisplatin alone or in combination is considered as the reference drug in combination with chemotherapy, but in the last decades, many trials have demonstrated that new-generation drugs, which are routinely used in metastatic disease, may be used during radiotherapy and may enhance its tumor control rate, frequently having a radiosentizing power. Finally, in the era of molecular biomarkers and target therapies, new approaches could dramatically change the physicians view about the drug choice giving the opportunity of a tailored therapy customized on the single patient also in the treatment of locally advanced non-small cell lung cancer.
Export Options
About this article
Cite this article as:
Caffo Orazio and Murgia Viviana, Radiochemotherapy for Non Small Cell Lung Cancer, Current Drug Therapy 2010; 5 (3) . https://dx.doi.org/10.2174/157488510791561084
DOI https://dx.doi.org/10.2174/157488510791561084 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
STAT3: A Molecular Target for Cancer Whose Time Has Come
Current Signal Transduction Therapy Current Status on Natural Products with Antitumor Activity from Brazilian Marine Sponges
Current Pharmaceutical Biotechnology Unexpected High Levels of Vorinostat when Combined with Vinorelbine in Patients with Advanced Cancer
Current Clinical Pharmacology The Radio-Sensitizing Effect of Pharmacological Concentration of Ascorbic Acid on Human Pancreatic Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Monitoring T Cell Responses to Cancer Immunotherapy: Can We Now Identify Biomarkers Predicting Patients Who will be Responders
Current Cancer Therapy Reviews Molecular Aspects of FKBP51 that Enable Melanoma Dissemination
Current Molecular Pharmacology ABC Transporters as Potential Targets for Modulation of Drug Resistance
Mini-Reviews in Medicinal Chemistry Toxicity of Carbon Nanotubes
Current Drug Metabolism Targeting the Eph System with Peptides and Peptide Conjugates
Current Drug Targets Diterpenoids from Liverworts and their Biological Activities
Current Organic Chemistry Targeting DNA Topoisomerase I with Non-Camptothecin Poisons
Current Medicinal Chemistry Eicosanoids in Prevention and Management of Diseases
Current Molecular Medicine Mechanism of Conjugated Imine and Iminium Species, including Marine Alkaloids: Electron Transfer, Reactive Oxygen Species, Therapeutics and Toxicity
Current Bioactive Compounds Heparanase Patents: Dim Past and Bright Future
Recent Patents on Inflammation & Allergy Drug Discovery Novel Glycomimetics: Anomeric and N-Glycosyl Sulfonamides
Current Organic Chemistry The Role of Tumor Associated Macrophages in the Tumor Microenvironment: Mechanism and Functions
Anti-Cancer Agents in Medicinal Chemistry Vascular Endothelial Growth Factor (VEGF) Biochemistry and Development of Inhibitory Drugs
Current Drug Therapy DNA Methyltransferase-1 Inhibitors as Epigenetic Therapy for Cancer
Current Cancer Drug Targets Well-defined Graphene Oxide as a Potential Component in Lung Cancer Therapy
Current Cancer Drug Targets Approaches to Target Profiling of Natural Products
Current Medicinal Chemistry